Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...
Fintech giant Groww is reportedly gearing up to file for an initial public offering (IPO) in the next 10-12 months ...
Titan America SA, the US unit of Titan Cement International SA, has filed for an initial public offering in New York, showing ...
Antharas said it expects the IPO to price between $4 and $5 per share. The company applied to list on the Nasdaq Capital Market under the symbol AAS. For the year ended Dec. 31, 2023, the company ...
Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...
It would be the first life sciences IPO since BioAge Labs' offering in September. Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of ...
Titan America, a manufacturer and supplier of heavy building materials and services, plans to sell shares through an initial public offering, according to a Securities and Exchange Commission filing ...
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...
Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...
Gold jewellery maker Shanti Gold International has filed preliminary papers with SEBI to raise funds via initial public ...